NCT04657094View on ClinicalTrials.gov

Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

April 1, 2023

Study Completion Date

February 27, 2026

Conditions
Autoimmune Hemolytic AnemiaChronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWarm Antibody Autoimmune Hemolytic Anemia
Interventions
DRUG

Acalabrutinib

Given PO

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER